Company intelligence / Profile preview
Light Sciences Oncology
Bellevue, Washington, United Stateslife-sciences-usa.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Clinical trials demonstrated that talaporfin sodium activated by red light was safe and tolerable in glioblastoma patients, with evidence of tumor cell apoptosis and vessel closure. No dose-limiting toxicities or significant adverse neurologic sequelae were observed. Phase III trials were completed in hepatocellular carcinoma and metastatic colorectal cancer, but the company is now inactive.[5][8]
- Therapeutic areas
- OncologyMen's Health
- Modalities
- Small moleculeDevice (light-activated drug delivery)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Light Sciences Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Light Sciences Oncology.